Pfizer (NYSE: PFE) had big expectations for Inlyta when it launched in 2012. Over the past few years, though, it's fallen out of favor as new, more effective treatments set up camp in its neighborhood ...

NEW YORK -- A course of pills developed by Pfizer can slash the risk of being hospitalized or dying from COVID-19 by 89% if taken within three days of developing symptoms, according to results ...

Pfizer said Tuesday morning that final trial studies still show its experimental COVID-19 pill significantly reduced the risk of hospitalization or death linked to the virus by 89%. The company also ...

The announcement came as a real-world study from South Africa showed two doses of the Pfizer-BioNTech vaccine was 70 percent effective in stopping severe illness from the new variant, a result called ...

CHICAGO -- Pfizer has begun a Phase 2 and 3 clinical trial of its COVID-19 antiviral treatment, Paxlovid, in children ages 6 to 17, the company said Wednesday in a news release. The study will ...

Merck's and Pfizer's antiviral both work by preventing the virus from replicating. Merck's pill does so by introducing errors into the genetic code of the virus. Some of the FDA's experts have said ...

Separately, per the Pfizer-issued report, interim analyses of an ongoing second study in standard-risk adults (EPIC-SR) showed a 70% reduction in hospitalization and no deaths in the treated ...

Pfizer said Tuesday it signed a licensing agreement to allow broader global access to its experimental COVID-19 pill. The agreement with the Medicines Patent Pool, a United Nations-backed public ...

In a statement issued Tuesday, Pfizer said it would grant a license for the antiviral pill to the Geneva-based Medicines Patent Pool, which would let generic drug companies produce the pill for use in ...